Vectra® DA is an advanced blood test for rheumatoid arthritis (RA) disease activity. Vectra® DA measures the levels of 12 protein biomarkers known to be important in RA and combines these levels into a single score, which can be used to provide a quantitative measure to objectively assess and track RA disease activity.
Personalizing Treatment Goals for Patients with Rheumatoid Arthritis
Regular, objective assessments of RA disease activity are critical for achieving target levels of disease activity and improving patient outcomes.1-7
Physicians typically use symptom assessments, joint evaluations and laboratory testing for C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR) to guide treatment goals for the management of RA. However, these measures cannot always identify underlying disease activity or accurately assess the risk of future joint damage, which may continue even when signs and symptoms appear to be controlled.8-10
Vectra® DA simultaneously measures 12 key biomarkers associated with RA disease activity and combines them into a single score between 1 and 100 (where a lower score indicates less disease activity).
By providing an objective and reproducible measure of RA disease activity that can be used alongside existing assessment tools, Vectra® DA helps patients with RA and their healthcare professionals to work together in determining individualized treatment goals.11,12
Patients and Physicians Work Together to Manage RA
Stephanie talks about how she has taken control of her life by tracking her disease and partnering with her rheumatologist.
1. Grigor C, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-269.
2. Rantalaiho V, et al, for the FIN-RACo Trial Group. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12(3):R122.
3. Verstappen SMM, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443-1449.
4. Goekoop-Ruiterman YPM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381-3390.
5. Saag KG, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784.
6. Combe B, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45.
7. Smolen JS, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637.
8. Barton JL, et al. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res. 2010;62:857-864.
9. Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%–45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol. 2009;36:1387-1390.
10. Brown AK, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58:2958-2967.
11. Curtis JR, et al. Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care & Research. 2012; 64 (12):1794-1803.
12. Hambardzumyan K, et al. Pre-treatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis 2014. doi:10.1136/annrheumdis-2013-204986